Cargando…

Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients

Autologous stem cell transplant (aHSCT) is associated with improved survival for multiple myeloma (MM) patients but may be associated with second primary malignancy (SPM) development. Using the California Cancer Registry linked to statewide hospitalization data, we determined the cumulative incidenc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosenberg, A. S., Brunson, A., Tuscano, J., Jonas, B. A., Hoeg, R., Wun, T., Keegan, T. H. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791054/ https://www.ncbi.nlm.nih.gov/pubmed/33414400 http://dx.doi.org/10.1038/s41408-020-00400-4

Ejemplares similares

Update on the Role of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Tosi, P., et al.
Publicado: (2012)

Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Tuchman, S. A., et al.
Publicado: (2012)

Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation
por: Al-Anazi, Khalid Ahmed
Publicado: (2012)

SECOND MALIGNANCIES AFTER AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN
por: Danner-Koptik, Karina E, et al.
Publicado: (2012)

Sequential, Autologous Hematopoietic Stem Cell Transplant Followed by Renal Transplant in Multiple Myeloma
por: Bhowmik, D., et al.
Publicado: (2017)

Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients
por: FU, CHENGCHENG, et al.
Publicado: (2013)

Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance
por: Rosenberg, A S, et al.
Publicado: (2017)

Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis
por: Ragon, Brittany Knick, et al.
Publicado: (2023)

Tandem Autologous Hematopoietic Stem Cell Transplantation in Very Young Patients with Multiple Myeloma
por: Naithani, Rahul, et al.
Publicado: (2020)

Membranous Glomerulopathy After Autologous Hematopoietic Stem Cell Transplant in a Patient With Multiple Myeloma
por: Rodríguez Feria, Daniela, et al.
Publicado: (2021)

Outcomes of Salvage Autologous Versus Allogeneic Hematopoietic Cell Transplantation for Relapsed Multiple Myeloma After Initial Autologous Hematopoietic Cell Transplantation
por: Wirk, Baldeep, et al.
Publicado: (2013)

Management of central nervous system involvement in multiple myeloma after autologous hematopoietic stem cell transplantation
por: Mousavi-Fatemi, Khatereh, et al.
Publicado: (2020)

Trends in utilization of stored cryopreserved autologous peripheral hematopoietic cells intended for a second (or beyond) autologous hematopoietic cell transplantation in patients with multiple myeloma: a single center experience
por: Yassine, Farah, et al.
Publicado: (2023)

Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma
por: Green, Damian J., et al.
Publicado: (2016)

Autologous Graft-Versus-Host Disease of the Gastrointestinal Tract in Patients With Multiple Myeloma and Hematopoietic Stem Cell Transplantation
por: Hammami, Muhammad B., et al.
Publicado: (2018)

Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma
por: Maffini, Enrico, et al.
Publicado: (2019)

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation
por: Uy, Geoffrey L., et al.
Publicado: (2015)

Prevalence and Significance of Sarcopenia in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
por: Williams, Alexis, et al.
Publicado: (2020)

Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma
por: Kansagra, Ankit, et al.
Publicado: (2022)

Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma
por: Cox, J E, et al.
Publicado: (2014)

Current status of autologous stem cell transplantation for multiple myeloma
por: Al Hamed, Rama, et al.
Publicado: (2019)

Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma
por: Paquin, Ashley, et al.
Publicado: (2020)

Non-Cryopreserved Peripheral Blood Stem Cell Graft for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma and Lymphoma Patients
por: Noiperm, Panarat, et al.
Publicado: (2023)

Autologous transplant and second malignancies in MM
por: Pasvolsky, Oren, et al.
Publicado: (2023)

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
por: Yarlagadda, Lakshmi, et al.
Publicado: (2021)

Successful Treatment of Gastric Relapse in Multiple Myeloma with Bortezomib after Autologous Hematopoietic Stem Cell Transplantation (autoHSCT)
por: Sivgin, Serdar, et al.
Publicado: (2013)

Detection of Minimal Residual Disease by Flow Cytometry for Patients with Multiple Myeloma Submitted to Autologous Hematopoietic Stem Cell Transplantation
por: Dal Bó, Suzane, et al.
Publicado: (2013)

C-Reactive Protein Monitoring Predicts Neutropenic Fever Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
por: Kollu, Vidya, et al.
Publicado: (2018)

Prognostic Significance of Blood Transfusion in Newly Diagnosed Multiple Myeloma Patients without Autologous Hematopoietic Stem Cell Transplantation
por: Fan, Liping, et al.
Publicado: (2017)

Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma
por: Srour, Samer A., et al.
Publicado: (2021)

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial
por: Crees, Zachary D., et al.
Publicado: (2023)

P1375: SECOND PRIMARY MALIGNANCY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Tan, T.-D., et al.
Publicado: (2022)

Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs
por: Takamatsu, Hiroyuki, et al.
Publicado: (2023)

Autologous hematopoietic stem cell transplantation in progressive severe multiple sclerosis
por: Pandit, Awadh Kishor, et al.
Publicado: (2015)

Regenerating Immunotolerance in Multiple Sclerosis with Autologous Hematopoietic Stem Cell Transplant
por: Massey, Jennifer C., et al.
Publicado: (2018)

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for 30-Day Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma
por: Jaglowski, Samantha M., et al.
Publicado: (2014)

Complete response after autologous stem cell transplant in multiple myeloma
por: Kumar, Lalit, et al.
Publicado: (2014)

Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma
por: Al-Mansour, Zeina, et al.
Publicado: (2014)

Interrupted Identities: Autologous Stem Cell Transplant in Patients With Multiple Myeloma
por: Halpin, Sean N, et al.
Publicado: (2021)

Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia
por: Abdrabou, Ahmed Kotb, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_anlcmarh4kiasqq6jk7e1es1o2